Journal Article

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Husmark, Tomas, Ørnbjerg, Lykke Midtbøll, Grøn, Kathrine Lederballe, Kononoff, Aulikki, Rezaei, Hamed, Giovanni, Cagnotto, Hauge, Ellen-Margrethe, Lindqvist, Elisabet, Klint, Erik af, Parmanne, Pinja, Hetland, Merete Lund, Rizk, Milad, Rødevand, Erik, Christiansen, Sara Nysom, Just, Søren Andreas, Hemberg, Malin, Kastbom, Alf, Hansen, Inger MarieJensen, Hermansson, Elsa, Stilling-Vinther, Maria K, Grenholm, Emma, Wallman, Johan, Rudin, Anna, Söderbergh, Annika, Sokka, Tuulikki, Bengtsson, Anders, Leirisalo-Repo, Marjatta, Haavardsholm, Espen A, Østergaard, Mikkel, Aga, Anna-Birgitte, Einarsson, Jon, Relas, Heikki, Brodin, Eli, Larsson, Per, Nurmohamed, Michael T, Bøyesen, Pernille, Öberg, Kajsa, Rannio, Tuomas, Bakland, Gunnstein, Karlberg, Lena, Blanken, Annelies, Uhrenholt, Line, Krabbe, Simon, Rutanen, Jarno, Jensen, Pia Neuer, Exarchou, Sofia, Bruun, Trude, Turesson, Carl, Lindqvist, Joakim, Lend, Kristina, Ellingsen, Torkell, Hendricks, Oliver, Valleala, Heikki, Lindell, Pia, Gentline, Cidem, Faustini, Francesca, Almehed, Katarina, Vedder, Daisy, Hørslev-Petersen, Kim, Rathmann, Jens, Tuompo, Riitt

2023

Overview

The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with different modes of action. Investigator-initiated, randomised, blinded-assessor study. Patients with treatment-naïve early RA with moderate-severe disease activity were randomised 1:1:1:1 to methotrexate combined with (1) active conventional therapy: oral prednisolone (tapered quickly, discontinued at week 36) sulfasalazine, hydroxychloroquine and intra-articular glucocorticoid injections in swollen joints; (2) certolizumab pegol; (3) abatacept or (4) tocilizumab. Coprimary endpoints were week 48 Clinical Disease Activity Index (CDAI) remission (CDAI ≤2.8) and change in radiographic van der Heijde-modified Sharp Score, estimated using logistic regression and analysis of covariance, adjusted for sex, anticitrullinated protein antibody status and country. Bonferroni's and Dunnet's procedures adjusted for multiple testing (significance level: 0.025). Eight hundred and twelve patients were randomised. Adjusted CDAI remission rates at week 48 were: 59.3% (abatacept), 52.3% (certolizumab), 51.9% (tocilizumab) and 39.2% (active conventional therapy). Compared with active conventional therapy, CDAI remission rates were significantly higher for abatacept (adjusted difference +20.1%, p<0.001) and certolizumab (+13.1%, p=0.021), but not for tocilizumab (+12.7%, p=0.030). Key secondary clinical outcomes were consistently better in biological groups. Radiographic progression was low, without group differences.The proportions of patients with serious adverse events were abatacept, 8.3%; certolizumab, 12.4%; tocilizumab, 9.2%; and active conventional therapy, 10.7%. Compared with active conventional therapy, clinical remission rates were superior for abatacept and certolizumab pegol, but not for tocilizumab. Radiographic progression was low and similar between treatments. NCT01491815.

• Publisher: Elsevier Limited
• Subject: Abatacept / Abatacept - therapeutic use / Antibiotics / Antirheumatic Agents - adverse effects / Arthritis, Rheumatoid - chemically induced / Arthritis, Rheumatoid - diagnostic imaging / Arthritis, Rheumatoid - drug therapy / Autoimmunitet och inflammation / Autoimmunity and Inflammation / Biological Therapy / Certolizumab pegol / Certolizumab Pegol - therapeutic use / Clinical Medicine / Disease / Drug Therapy, Combination / Glucocorticoids / Humans / Hydroxychloroquine / Joint diseases / Klinisk medicin / Medical and Health Sciences / Medicin och hälsovetenskap / Methotrexate / Methotrexate - therapeutic use / Monoclonal antibodies / Patients / Prednisolone / Proteins / Questionnaires / Remission / Remission (Medicine) / Rheumatoid Arthritis / Rheumatology / Sulfasalazine / Treatment Outcome / Tumor necrosis factor-α